Nexalin Technology, Inc. is a publicly traded company focused on the development and commercialization of innovative therapeutic technologies designed to improve mental health and wellness
The company specializes in non-invasive neurostimulation therapies that target various mental health conditions, offering potential alternative treatment options. By integrating advanced technology with a commitment to research and development, Nexalin aims to enhance the quality of life for individuals seeking effective solutions to manage their mental health challenges.
Nexalin Technology's clinical trial results highlight notable cognitive improvements in Alzheimer's patients using Deep Intracranial Frequency Stimulation technology. The study showed significant memory and cognition gains, increased hippocampal activity, and minimal side effects.
Nexalin Technology, Inc. (NASDAQNXL) shares surged on Friday afternoon following the announcement of a new patent awarded by the United States Patent and Trademark Office (USPTO).
Nexalin Technology has received U.S. patent for its non-invasive Deep Intracranial Frequency Stimulation device for Alzheimer's and dementia. The device is part of a market projected to reach over $28 billion by 2030.
